{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:26:19Z","timestamp":1762543579964},"reference-count":0,"publisher":"Frontline Medical Communications, Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"DOI":"10.12788\/cutis.0423","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T19:28:05Z","timestamp":1644953285000},"source":"Crossref","is-referenced-by-count":5,"title":["Herpes Zoster Following a Nucleoside-Modified Messenger RNA COVID-19 Vaccine"],"prefix":"10.12788","volume":"109","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Dezoteux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5043","published-online":{"date-parts":[[2022,1,1]]},"container-title":["Cutis"],"original-title":[],"link":[{"URL":"https:\/\/cdn.mdedge.com\/files\/s3fs-public\/CT109001005_e.PDF","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T19:28:06Z","timestamp":1644953286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdedge.com\/dermatology\/article\/250434\/infectious-diseases\/herpes-zoster-following-nucleoside-modified-messenger"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,1]]},"published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.12788\/cutis.0423","relation":{},"subject":[],"published":{"date-parts":[[2022,1,1]]}}}